WCN25-3301 Flozination in kidney transplant recipients: is it safe?

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been established as antiproteinuric and nephroprotective agents in diabetic as well as non diabetic proteinuric diseases of the kidney. Despite the evidence for both renoprotective and cardioprotective effects, their use in the post kidney transplant setting is limited. There is a dearth of studies on the safety of their use in this population group. This is a retrospective study on the safety and efficacy of SGLT2i in the post renal transplant patients.